IL2 and cancer: It has been demonstrated that PD-1 blockade reinvigorates IL-2 production in T cells,22 and this is an important mechanism for the effectiveness of cancer immunotherapies, as IL-2 neutralization or CD25 blockage strongly diminishes the antitumor efficacy of PD-1 blockade.22